Literature DB >> 16421738

Abundant hypermethylation of SOCS-1 in clinically silent pituitary adenomas.

Rolf Buslei1, Jürgen Kreutzer, Bernd Hofmann, Verena Schmidt, Florian Siebzehnrübl, Eric Hahnen, Ilker Y Eyupoglu, Rudolf Fahlbusch, Ingmar Blümcke.   

Abstract

Janus kinase (JAK)/signal transducers and activators of transcription (STAT) cascade are required for cytokines, growth factors, G-proteins and hormones (growth hormone and prolactin). Gatekeepers in this pathway are the suppressor of cytokine signalling (SOCS) family of proteins. Their expression level is epigenetically regulated by DNA methylation. We have investigated the CpG island methylation status of SOCS-1 in a cohort of pituitary adenomas (PA; n=57), craniopharyngiomas (CP; n=30) and normal pituitary tissue (NP; n=11) using methylation sensitive single-strand conformation polymorphism analysis (MS-SSCP) and direct sequencing. SOCS-1 hypermethylation was identified in 51% (29/57) of surgical specimens obtained from PA patients. 83% of these tumours were clinically silent. In contrast, no methylation of SOCS-1 was observed in CPs or NPs. Quantitative real-time PCR and western blot analysis confirmed reduced SOCS-1 expression in the majority of pituitary adenomas. The data is compatible with epigenetic silencing of the SOCS-1 gene and constitutive activation of the JAK-STAT pathway in PA. This appears to contribute particularly to those tumours characterized by a hormone-inactive status.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421738     DOI: 10.1007/s00401-005-0009-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  9 in total

1.  Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis.

Authors:  R C Sobti; Neha Singh; Showket Hussain; Vanita Suri; Raje Nijhawan; A C Bharti; Mausumi Bharadwaj; B C Das
Journal:  Cell Oncol (Dordr)       Date:  2011-09-21       Impact factor: 6.730

Review 2.  Epigenetic mechanisms in Alzheimer's disease.

Authors:  Diego Mastroeni; Andrew Grover; Elaine Delvaux; Charisse Whiteside; Paul D Coleman; Joseph Rogers
Journal:  Neurobiol Aging       Date:  2011-04-11       Impact factor: 4.673

3.  SOCS2 polymorphisms are not associated with clinical and biochemical phenotypes in acromegalic patients.

Authors:  Ericka B Trarbach; Alexander A Jorge; Felipe H Duarte; Marcello D Bronstein; Raquel S Jallad
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

4.  Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line.

Authors:  Paweena Chunharojrith; Yuki Nakayama; Xiaobing Jiang; Rachel E Kery; Jun Ma; Cristine S De La Hoz Ulloa; Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2015-08-15       Impact factor: 4.102

Review 5.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

6.  Genome-wide identification of lncRNAs and mRNAs differentially expressed in non-functioning pituitary adenoma and construction of an lncRNA-mRNA co-expression network.

Authors:  Weikang Xing; Zhenyu Qi; Cheng Huang; Nan Zhang; Wei Zhang; Yao Li; Minyan Qiu; Qi Fang; Guozhen Hui
Journal:  Biol Open       Date:  2019-01-04       Impact factor: 2.422

Review 7.  The Genetics of Pituitary Adenomas.

Authors:  Christina Tatsi; Constantine A Stratakis
Journal:  J Clin Med       Date:  2019-12-21       Impact factor: 4.241

8.  STAT2*C related genotypes and allele but not TLR4 and CD40 gene polymorphisms are associated with higher susceptibility for asthma.

Authors:  Yao-Yuan Hsieh; Lei Wan; Chi-Chen Chang; Chang-Hai Tsai; Fuu-Jen Tsai
Journal:  Int J Biol Sci       Date:  2009-01-09       Impact factor: 6.580

Review 9.  Animal models of pituitary neoplasia.

Authors:  K E Lines; M Stevenson; R V Thakker
Journal:  Mol Cell Endocrinol       Date:  2015-08-28       Impact factor: 4.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.